A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Status:
Completed
Trial end date:
2020-03-26
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the efficacy and safety of ASP1517 when converted
from recombinant human erythropoietin (rHuEPO) or darbepoetin alfa (DA), compared to DA in
the treatment of anemia in non-dialysis chronic kidney disease patients. Another uncontrolled
cohort will be included to evaluate the efficacy and safety of ASP1517 in patients converted
from epoetin beta pegol (CERA). This study will also assess the safety/efficacy of long term
treatment of ASP1517 (52 weeks).